DrugBiological
Bavituximab clinical trials
- studies test it
- 25
- open now
- 0
- in phase 3
- 2
- first study started
- 2005
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
25 studies that test it; most in 2011 (6)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2010 | 1 |
| 2011 | 6 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 16
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 10
Peregrine Pharmaceuticals (14) · University of Texas Southwestern Medical Center (3) · University of Maryland, Baltimore (1) · David Hsieh (1) · Massachusetts General Hospital (1) · OncXerna Theraputics, Inc. (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Arizona (1)
Often tested with
Tested in the same studies.
Pembrolizumab (3) · Sorafenib (2) · Paclitaxel (2) · Temozolomide (1) · Capecitabine (1) · Carboplatin (1) · Axitinib (1) · Avelumab (1)
Studies
Open first, then newest update. How each study uses bavituximab is read from its arms, and is right about nine times in ten.
Testing it · 25
- A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular CarcinomaCompletedPhase 2David HsiehNCT03519997Written as Bavituximab
- 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and NeckActive, not recruitingPhase 2University of Maryland, BaltimoreNCT04150900Written as Bavituximab
- Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed GlioblastomaCompletedPhase 2Massachusetts General HospitalNCT03139916Written as Bavituximab
- Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular CarcinomaTerminatedPhase 2University of Texas Southwestern Medical CenterNCT05249569Written as Bavituximab
- An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer PatientsCompletedPhase 2OncXerna Theraputics, Inc.NCT04099641Written as Bavituximab
- Study of Bavituximab and Sorafenib In Patients With Advanced Liver CancerCompletedPhase 1/2University of Texas Southwestern Medical CenterNCT01264705Written as bavituximab (0.3 mg/kg) and sorafenib
- A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal AdenocarcinomaCompletedPhase 1University of Texas Southwestern Medical CenterNCT01634685Written as Bavituximab
- Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular CarcinomaWithdrawnPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT02989870Written as Bavituximab
- Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) SubjectsCompletedPhase 1UNC Lineberger Comprehensive Cancer CenterNCT01323062Written as Bavituximab
- Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate CancerTerminatedPhase 1/2Medical University of South CarolinaNCT01335204Written as Cabazitaxel plus bavituximab
- Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast CancerWithdrawnPhase 2/3Peregrine PharmaceuticalsNCT02651610Written as Bavituximab
- Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung CancerCompletedPhase 3Peregrine PharmaceuticalsNCT01999673Written as bavituximab
- A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast CancerCompletedPhase 2Peregrine PharmaceuticalsNCT00669591Written as Bavituximab
- Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic CancerCompletedPhase 2Peregrine PharmaceuticalsNCT01272791Written as bavituximab
- Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung CancerCompletedPhase 2Peregrine PharmaceuticalsNCT01160601Written as bavituximab
- A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast CancerWithdrawnPhase 2Peregrine PharmaceuticalsNCT02685306Written as Bavituximab
- Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung CancerWithdrawnPhase 2Peregrine PharmaceuticalsNCT02673814Written as bavituximab
- Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast CancerCompletedPhase 1University of ArizonaNCT01288261Written as bavituximab
- Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 InfectionCompletedPhase 1/2Peregrine PharmaceuticalsNCT01273948Written as Bavituximab
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency VirusCompletedPhase 1Peregrine PharmaceuticalsNCT00503347Written as bavituximab
Codes
What other systems call bavituximab · ClinicalTrials.gg INT005588
- MeSH (NLM) C547825bavituximabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Q16CT95N25BAVITUXIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3637045bavituximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C49088BavituximabOne source FDA
- DrugBank DB05136One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C547825 | bavituximab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Q16CT95N25 | BAVITUXIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3637045 | bavituximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C49088 | Bavituximab | One source FDA |
| DrugBank | DB05136 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.